The rigorous process of testing vaccines for safety and efficacy
Before any vaccine reaches the public, it must undergo rigorous testing in clinical trials. These trials answer critical questions: Is the vaccine safe? Does it work? Who benefits most? What are the side effects?
Clinical trials follow a stepwise process that has been refined over decades. Each phase builds on the previous, with increasingly larger and diverse populations studied. This methodical approach ensures that by the time a vaccine is approved, we have substantial evidence of its safety and effectiveness.
This section explains how clinical trials work, what happens at each phase, and why the process matters for vaccine confidence.
20-100 participants. First human testing. Primary goal: assess safety and identify optimal dosage. Usually lasts several months.
Several hundred participants. Further evaluate safety and immune response. May compare different formulations or schedules. Usually lasts months to a couple years.
Thousands to tens of thousands of participants. Compare vaccinated vs. unvaccinated groups. Measures efficacy and rare side effects. Usually lasts 1-4 years.
Ongoing after approval. Monitors safety in millions of people. Identifies very rare side effects and long-term outcomes. Continues indefinitely.
Vaccine trials use specific methodological approaches to ensure reliable, unbiased results:
Participants are randomly assigned to vaccine or control group using computer-generated lists. This ensures both groups are similar in age, health status, and other factors — preventing selection bias.
In single-blind trials, participants don't know if they get vaccine or placebo. In double-blind trials, neither participants nor researchers know — preventing both placebo effects and researcher bias.
The control group receives either a placebo (inactive substance) or an existing vaccine for comparison. This allows measurement of the vaccine's effect above any placebo response.
Researchers must specify in advance exactly how they'll analyze data and what results would constitute "success." This prevents cherry-picking favorable results after the fact.
An "endpoint" is the specific outcome a trial is designed to measure. The choice of endpoint critically affects what conclusions can be drawn:
A trial that shows 95% efficacy against symptomatic infection doesn't necessarily mean 95% efficacy against transmission or severe disease. Understanding endpoints is key to interpreting results correctly.
Learn more about trial endpoints• FDA. "Vaccine Development: 101." U.S. Food and Drug Administration.
• WHO. "Guidelines on Clinical Evaluation of Vaccines." World Health Organization.
• IOM. Examining the Safety of Childhood Immunizations. Institute of Medicine; 1993.